Introduction
Methods
Patients
Perioperative management of antiplatelet therapy
Statistical analysis
Results
Total (n = 463) n (%) | APT (n = 48) n (%) | N-APT (n = 415) n (%) | P value | |
---|---|---|---|---|
Sex | 0.0276 | |||
Male | 281 (60.7) | 36 (75.0) | 245 (59.0) | |
Female | 182 (39.3) | 12 (25.0) | 170 (41.0) | |
Age (year old) [median (range)] | 67 (22–94) | 75 (52–90) | 67 (69–94) | < 0.0001 |
BMI [median (range)] | 22.4 (13.7–36.0) | 23.5 (15.9–32.7) | 22.4 (13.7–36.0) | 0.2262 |
ASA-class | < 0.0001 | |||
1 | 101 (21.8) | 2 (4.2) | 99 (23.9) | |
2 | 337 (72.8) | 34 (70.8) | 303 (73.0)) | |
3 | 25 (5.4) | 12 (25.0) | 13 (3.1) | |
PS | 0.0039 | |||
0 | 407 (87.9) | 36 (75.0) | 371 (89.4) | |
1 | 48 (10.4) | 12 (25.0) | 36 (8.7) | |
2 | 8 (1.7) | 0 | 8 (1.9) | |
Diabetes | 0.0018 | |||
Yes | 388 (83.8) | 16 (33.3) | 59 (14.2) | |
No | 75 (16.2) | 32 (66.7) | 356 (85.8) | |
VTE risk classification | 0.0058 | |||
Low | 67 (14.4) | 1 (2.1) | 66 (15.9) | |
High | 267 (57.7) | 29 (60.4) | 238 (57.4) | |
Highest | 129 (27.9) | 18 (37.5) | 111 (26.7) | |
Tumor location | 0.2391 | |||
Right | 148 (32.0) | 19 (39.6) | 129 (31.1) | |
Left | 142 (30.7) | 10 (20.8) | 132 (31.8) | |
Rectum | 173 (37.3) | 19 (39.6) | 154 (37.1) | |
Stage | 0.1282 | |||
0 | 27 (5.8) | 0 | 27 (6.5) | |
I | 225 (48.6) | 25 (52.1) | 200 (48.2) | |
II | 83 (18.0) | 7 (14.6) | 76 (18.3) | |
III | 101 (21.8) | 12 (25.0) | 89 (21.5) | |
IV | 27 (5.8) | 4 (8.3) | 23 (5.5) |
C-APT (n = 36) n (%) | I-APT (n = 10) n (%) | P value | |
---|---|---|---|
Sex | 0.7527 | ||
Male | 27 (75.0) | 7 (70.0) | |
Female | 9 (25.0) | 5 (33.3) | |
Age (year old) [median (range)] | 73 (52–85) | 78 (69–90) | 0.2092 |
BMI [median (range)] | 23.7 (17.1–32.7) | 21.0 (15.9–28.7) | 0.1874 |
ASA-class | 0.5532 | ||
1 | 2 (5.6) | 0 | |
2 | 25 (69.4) | 8 (80.0) | |
3 | 9 (25.0) | 2 (20.0) | |
PS | 0.2773 | ||
0 | 27 (75.0) | 9 (90.0) | |
1 | 9 (25.0) | 1 (10.0) | |
2 | 0 | 0 | |
Diabetes | 0.3206 | ||
Yes | 13 (36.1) | 2 (20.0) | |
No | 23 (63.9) | 8 (80.0) | |
VTE risk classification | 0.1314 | ||
Low | 0 | 1 (10.0) | |
High | 22 (61.1) | 7 (70.0) | |
Highest | 14 (38.9) | 2 (20.0) |
C-APT (n = 36) n (%) | I-APT (n = 10) n (%) | P value | |
---|---|---|---|
Operative time (min) [median (range)] | 305 (69–627) | 285 (158–372) | 0.4243 |
Blood loss (ml) [median (range)] | 57 (5–483) | 16 (5–240) | 0.0567 |
Intraoperative blood transfusion | – | ||
Yes | 0 | 0 | |
No | 36 (100) | 10 (100) | |
Open conversion | 0.3160 | ||
Yes | 2 (5.6) | 0 | |
No | 34 (94.4) | 10 (100) | |
Re-operation within 48 h | – | ||
Yes | 0 | 0 | |
No | 36 (100) | 10 (100) | |
Hb drop (> 2.0) | 0.1508 | ||
Yes | 4 (11.1) | 0 | |
No | 32 (88.9) | 10 (100) | |
Postoperative surgical sight bleeding | – | ||
Yes | 0 | 0 | |
No | 36 (100) | 10 (100) | |
Postoperative other sight bleeding | – | ||
Yes | 0 | 0 | |
No | 36 (100) | 10 (100) | |
VTE | 0.4811 | ||
Yes | 1 (2.8) | 0 | |
No | 35 (97.2) | 10 (100) | |
Cerebral or myocardial infarction | – | ||
Yes | 0 | 0 | |
No | 36 (100) | 10 (100) |
APT+ (n = 36) n (%) | APT− | ||||
---|---|---|---|---|---|
Overall (n = 425) n (%) | P value | After matching (n = 36) n (%) | P value | ||
Sex | 0.0569 | 0.7891 | |||
Male | 27 (75.0) | 252 (59.3) | 26 (72.2) | ||
Female | 9 (25.0) | 173 (40.7) | 10 (27.8) | ||
Age (year old) [median (range)] | 73 (52–85) | 67 (22–94) | < 0.0001 | 78 (57–90) | 0.4773 |
BMI [median (range)] | 23.7 (17.1–32.7) | 22.3 (13.7–36.0) | 0.0345 | 23.6 (15.9–30.1) | 0.7525 |
ASA-class | < 0.0001 | 0.8780 | |||
1 | 2 (5.6) | 99 (23.3) | 3 (8.3) | ||
2 | 25 (69.4) | 311 (73.2) | 25 (69.4) | ||
3 | 9 (25.0) | 15 (3.5) | 8 (22.2) | ||
VTE risk classification | 0.0018 | 0.4749 | |||
Moderate | 0 | 67 (15.8) | 0 | ||
High | 22 (61.1) | 245 (57.6) | 19 (52.8) | ||
Highest | 14 (38.9) | 113 (26.6) | 17 (47.2) | ||
Tumor location | 0.2834 | 0.9494 | |||
Right | 14 (38.9) | 134 (31.5) | 13 (36.1) | ||
Left | 7 (19.4) | 134 (31.5) | 8 (22.2) | ||
Rectum | 15 (41.7) | 157 (37.0) | 15 (41.7) | ||
Lymphadenectomy | 0.0212 | 1.0000 | |||
D2 | 27 (75.0) | 237 (55.8) | 27 (75.0) | ||
D3 | 9 (25.0) | 188 (44.2) | 9 (25.0) | ||
Surgical curability | 0.9213 | 0.5517 | |||
R0 | 34 (94.4) | 401 (94.4) | 35 (97.2) | ||
R1 | 0 | 1 (0.2) | 0 | ||
R2 | 2 (5.6) | 23 (5.4) | 1 (2.8) | ||
Stage | 0.1713 | 0.8632 | |||
0 | 0 | 27 (6.3) | 0 | ||
I | 21 (58.3) | 203 (47.8) | 24 (66.7) | ||
II | 4 (11.1) | 78 (18.3) | 3 (8.3) | ||
III | 9 (25.0) | 92 (21.7) | 8 (22.2) | ||
IV | 2 (5.6) | 25 (5.9) | 1 (2.8) |
APT+ (n = 36) n (%) | APT− (n = 36) n (%) | P value | |
---|---|---|---|
Operative time (min) [median (range)] | 305 (69–627) | 296 (158–539) | 0.8437 |
Blood loss (ml) [median (range)] | 57 (5–483) | 54 (7–359) | 0.5026 |
Intraoperative blood transfusion | – | ||
Yes | 0 | 0 | |
No | 36 (100) | 36 (100) | |
Open conversion | 1.0000 | ||
Yes | 2 (5.6) | 2 (5.6) | |
No | 34 (94.4) | 34 (94.4) | |
Re-operation within 48 h | – | ||
Yes | 0 | 0 | |
No | 36 (100) | 36 (100) | |
Hb drop (> 2.0) | 0.6903 | ||
Yes | 4 (11.1) | 3 (8.3) | |
No | 32 (88.9) | 33 (91.7) | |
Postoperative surgical sight bleeding | 0.2367 | ||
Yes | 0 | 1 (2.8) | |
No | 36 (100) | 35 (97.2) | |
Postoperative other sight bleeding | – | ||
Yes | 0 | 0 | |
No | 36 (100) | 36 (100) | |
VTE | 0.2367 | ||
Yes | 1 (2.8) | 0 | |
No | 35 (97.2) | 36 (100) | |
Cerebral or myocardial infarction | – | ||
Yes | 0 | 0 | |
No | 36 (100) | 36 (100) | |
Other complications (G2) | 0.5263 | ||
Yes | 7 (19.4) | 5 (13.9) | |
No | 29 (80.6) | 31 (86.1) | |
Other complications (> G3) | 0.3231 | ||
Yes | 7 (19.4) | 4 (11.1) | |
No | 29 (80.6) | 32 (88.9) | |
Mortality (within 1 month) | – | ||
Yes | 0 | 0 | |
No | 36 (100) | 36 (100) | |
Period of hospital stay (day) [median (range)] | 12 (7–126) | 11 (7–91) | 0.1586 |